Bortezomib (PS-341): Advancing Proteasome Inhibitor Research in Cancer and Mitochondrial Proteostasis

Introduction

Proteostasis—the finely tuned balance between protein synthesis, folding, and degradation—serves as a cornerstone of cellular homeostasis and disease prevention. Central to this process is the ubiquitin-proteasome system (UPS), which orchestrates the selective removal of damaged or regulatory proteins. Aberrant proteasome activity is implicated in cancer, neurodegeneration, and metabolic disorders. Bortezomib (PS-341) is a clinically validated, reversible proteasome inhibitor that has transformed both therapeutic and laboratory approaches to targeting the 20S proteasome and elucidating programmed cell death mechanisms. While substantial literature addresses Bortezomib’s direct effects on cancer cell viability, this article synthesizes emerging evidence on its utility in interrogating mitochondrial proteostasis and metabolic regulation, offering a distinct perspective beyond canonical apoptosis assay applications.

Mechanism of Action: 20S Proteasome Inhibition and Proteasome-Regulated Cellular Processes

Bortezomib (PS-341) is chemically defined as an N-terminally protected dipeptide (Pyz-Phe-boroLeu) incorporating pyrazinoic acid, phenylalanine, and leucine, capped by a boronic acid moiety. Its mode of action centers on the reversible inhibition of the 20S proteasome’s chymotrypsin-like activity, preventing the degradation of ubiquitinated proteins. This blockade results in the accumulation of pro-apoptotic and regulatory proteins, thereby activating cell death programs and modulating proteasome signaling pathways. The compound demonstrates remarkable potency, with an IC₅₀ of 0.1 µM in H460 non-small cell lung carcinoma cells and low nanomolar activity (3.5–5.6 nM) in canine malignant melanoma models, underscoring its utility as a proteasome inhibitor for cancer therapy.

Bortezomib in Cancer Research: From Multiple Myeloma to Mantle Cell Lymphoma

The clinical approval of Bortezomib for relapsed multiple myeloma and mantle cell lymphoma established a new paradigm for targeting proteostasis in cancer. By impeding proteasomal degradation, Bortezomib promotes the stabilization of tumor suppressors such as p53 and pro-apoptotic factors including Bax and NOXA, while suppressing NF-κB signaling. In xenograft mouse models, intravenous administration of Bortezomib at 0.8 mg/kg achieved significant tumor growth suppression, corroborating its in vivo efficacy. These findings have propelled the compound into the forefront of multiple myeloma research and mantle cell lymphoma research, where it remains a benchmark for drug development and mechanistic studies.

Expanding Horizons: Bortezomib as a Tool for Exploring Mitochondrial Proteostasis

Recent advances in mitochondrial biology have illuminated the intricate interplay between mitochondrial proteostasis and cellular metabolism. Mitochondrial chaperones and proteases—such as HSPA9 (mtHSP70), LONP1, and the DNAJC family—ensure the fidelity of mitochondrial protein turnover, impacting energy production and metabolic signaling. Of particular interest is the regulation of the α-ketoglutarate dehydrogenase (OGDH) complex, a rate-limiting enzyme in the TCA cycle. In a landmark study by Wang et al. (Molecular Cell, 2025), the mitochondrial co-chaperone TCAIM was shown to reduce OGDH protein levels via HSPA9 and LONP1, thus modulating mitochondrial metabolism and carbohydrate catabolism.

This discovery highlights the convergence of proteasome-regulated cellular processes at the intersection of cytosolic and mitochondrial proteostasis. While Bortezomib (PS-341) primarily targets the cytosolic 20S proteasome, its research applications enable investigators to probe upstream and downstream effects on mitochondrial protein quality control and metabolic adaptation. For example, proteasome inhibition may induce compensatory changes in mitochondrial chaperone activity or substrate flux through the TCA cycle, providing a mechanistic link between proteostasis disruption and altered metabolic states.

Practical Guidance: Experimental Use of Bortezomib (PS-341) in Proteostasis and Apoptosis Assays

To maximize reproducibility and compound integrity in experimental settings, Bortezomib should be dissolved in DMSO (≥19.21 mg/mL), as it is insoluble in water and ethanol. Stock solutions should be stored at or below –20°C and protected from freeze-thaw cycles to prevent degradation. For in vitro studies, nanomolar to low micromolar concentrations are typically sufficient for robust proteasome inhibition, while in vivo efficacy has been demonstrated at 0.8 mg/kg intravenously in murine models. When designing apoptosis assays or studies of programmed cell death mechanisms, researchers should consider time-course analyses and orthogonal readouts (e.g., caspase activation, mitochondrial membrane potential, and TUNEL staining) to distinguish direct proteasome effects from secondary mitochondrial adaptations.

Moreover, the use of Bortezomib in tandem with mitochondrial metabolic inhibitors or genetic models (such as TCAIM or OGDH knockdown) offers a powerful strategy to dissect the crosstalk between UPS-mediated degradation and mitochondrial proteostasis. As shown in the study by Wang et al. (Molecular Cell, 2025), post-translational regulation of OGDH by mitochondrial chaperones is crucial for metabolic plasticity, and perturbations of the UPS may influence these pathways in cancer and metabolic disease contexts.

Novel Insights: Connecting Proteasome Inhibition to Mitochondrial Metabolic Regulation

Integrating the findings from Bortezomib-based research with the emerging understanding of mitochondrial proteostasis opens new avenues for studying cancer metabolism and drug resistance. For instance, proteasome inhibition can activate the unfolded protein response (UPR_mt) and facilitate retrograde signaling between mitochondria and the nucleus, potentially altering the expression of metabolic enzymes and stress response factors. The evidence provided by Wang et al. (2025) establishes a precedent for investigating how proteostasis regulators, such as TCAIM, interface with metabolic control points like OGDH, suggesting that dual targeting of proteasomal and mitochondrial quality control may offer synergistic therapeutic benefits.

Furthermore, Bortezomib’s reversible mode of action allows for temporal dissection of proteasome-regulated cellular processes and their impact on mitochondrial function. This is particularly relevant for modeling adaptive responses in cancer cells, where metabolic reprogramming supports survival under proteotoxic stress. By combining proteasome inhibition with metabolic flux analysis, researchers can delineate how disruptions in protein degradation intersect with cellular energy production, biosynthetic capacity, and redox homeostasis.

Conclusion

Bortezomib (PS-341) is more than a cornerstone proteasome inhibitor for cancer therapy; it is a versatile probe for unraveling the broader landscape of proteostasis and metabolic regulation. Its unique chemical properties and potent, reversible inhibition of the 20S proteasome make it indispensable for studies of apoptosis, proteasome signaling pathways, and increasingly, mitochondrial proteostasis. By integrating Bortezomib into experimental designs that interrogate both cytosolic and mitochondrial protein quality control, researchers can gain unprecedented insights into the molecular determinants of cell fate and metabolic adaptation in health and disease.

This article extends the discussion beyond established themes, such as those explored in "Bortezomib (PS-341): Mechanistic Insights into Reversible...", by explicitly addressing the interface between reversible proteasome inhibition and mitochondrial proteostasis, with a focus on recent mechanistic findings involving TCAIM and OGDH regulation. By situating Bortezomib research in the context of emerging mitochondrial quality control paradigms and metabolic signaling, this piece provides both conceptual and practical guidance for investigators seeking to bridge these interconnected domains.